Malaria

Novartis Pledges to Fight Tropical Diseases and Malaria

Swiss drugmaker Novartis has made a five-year financial commitment of $250 million to fight neglected tropical diseases (NTDs) and malaria.

News

BioNTech Developing new Malaria Vaccine

BioNTech has launched a new project aimed at developing what it hopes will be a well-tolerated and highly effective malaria vaccine for the African continent. The Mainz, Germany-based company, which developed a Covid-19 vaccine together with Pfizer in only ten months, said its goal is to produce the malaria vaccine locally.

Top-Feature

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Aenova Holding GmbH

Mastering Modified Release: The Pellet-Based Approach

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Novartis Pharma GmbH